Hypercholesterlemia Hypercholesterlemia, Low Density Lipoprotein-Cholesterol, LDL-C
Conditions
Interventions
Naive group
1. Crestor group : Crestor 10 mg/day, appointment at 2, 4 and 6 weeks
2. Kzuva group : Kzuva 10 mg/day, appointment at 2, 4 and 6 weeks,Failure statin dose 20 mg
1. Crestor group : Crestor
Naive,Failure statin dose 20 mg,Failure statin dose 20 mg,Failure statin dose 40 mg
Sponsors
Health System Research Institute
Eligibility
Sex/Gender
All
Age
35 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >/= 35 years 2. LDL-C level according to criteria
Exclusion criteria
Exclusion criteria: 1. Uncontrolled DM within 3 mounts before screening visit or HbA1C >8% 2. Serum triglyceride >/= 500mg/dL 3. History of uncontrolled thyroid disease with in 1 year before screening 4. History of gastrointestinal disease 5. AST, ALT, alkaline phosphate, bilirubin any value more than 2 times of upper limit of normal for the reference laboratory 6. Serum creatinine more than 2 .0 mg/dL 7. Creatinine phosphokinase(CPK) more than 2-fold the upper limit of normal 8. Uncontrolled hypertension(DBP > 100 mmHg or SBP > 160 mmHg) 9. Unstable angina, Congestive heart failure or orther uncontrolled cardiac disease 10. Female who is pregnant or breast-feeding 11. History of substance abuse or have a mental illness that may affect protocol compliance 12. History of take dietary supplement products that have medical evidence for reduce lipid level 13. Drinking every day (Beer more than 12 ounce, Wine more than 6 ounce or Alcohol more than 2 ounce) 14. Any disorder, which in the investigator's opinion might jeopardise patient's safety or compliance with the protocol 15. Participation in any clinical trial with in 30 days before screening 16. History of any medication taken that may interact with rosuvastatin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LDL-C at 6 week after enrollment LDL-C level | — |
Secondary
| Measure | Time frame |
|---|---|
| Total cholesterol at 6 week after enrollment Percentage of change of total cholesterol level,Triglycerides at 6 week after enrollment Percentage of change of triglyceride level,HDL-C at 6 week after enrollment Percentage of change of HDL-C level,Complication at 6 week after enrollment Percentage of subject who have complication from study drug | — |
Countries
Thailand
Contacts
Public ContactSaranyou Suwanugsorn
Faculty of Medicine Prince of Songkla University
Outcome results
None listed